Paltusotine hydrochloride is under clinical development by Crinetics Pharmaceuticals and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Paltusotine hydrochloride’s likelihood of approval (LoA) and phase transition for Carcinoid Syndrome (Malignant Carcinoid Syndrome) took place on 20 Dec 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Paltusotine hydrochloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Paltusotine hydrochloride overview
Paltusotine hydrochloride (CRN-00808) is under development for the treatment of acromegaly and neuroendocrine tumors, carcinoid syndfrome. The drug candidate is administered through oral route. The drug candidate is a biased nonpeptide acts by targeting somatostatin receptor. The drug candidate was under development for age-related macular degeneration (AMD) and diabetic retinopathy.
Crinetics Pharmaceuticals overview
Crinetics Pharmaceuticals (Crinetics) is a pharmaceutical company. It developes of novel therapeutics targeting peptide hormone receptors for the treatment of rare endocrine disorders and endocrine-related cancers. The company’s products portfolio comprises paltusotine (Oral SST2 agonist); CRN04777 (SST5 agonist); and CRN04894 (ACTH agonist). It provides somatostatin agonists for the treatment of pancreatic neuroendocrine tumors, carcinoid tumors, GH secreting adenomas, diabetic retinopathy, graves ophthalmopathy, chronic pain, epilepsy, and dementia. The company provides endocrine drug discovery and development through collaboration with healthcare and research institutes. Crinetics is headquartered in San Diego, California, the US.
Quick View Paltusotine hydrochloride LOA Data
Report Segments |
|
Drug Name |
|
Administration Pathway |
|
Therapeutic Areas |
|
Key Developers |
|
Highest Development Stage |
|